Payment overview · 2025
General Payments
$109,428.06
194 reported records · 11 companies
Healthcare provider profile · identity verified
William Douglas King, MD, JD
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1427079250
Verified facts
What the public records show
CMS Open Payments records show William Douglas King, MD, JD received $109,428.06 in general payments during 2025 across 194 reported records.
ViiV Healthcare Company accounted for 58.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Dovato, Farxiga, Jardiance, Kerendia, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Biktarvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $63,870.03 | 58.4% | 74 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $44,638.57 | 40.8% | 95 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $294.27 | 0.3% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $214.45 | 0.2% | 6 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $115.32 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $96.95 | 0.1% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $53.43 | 0.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.46 | 0.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.28 | 0.0% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $30.29 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.01 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $79,252.50 | 26 |
| Travel and Lodging | $15,176.62 | 39 |
| Consulting Fee | $9,500.00 | 2 |
| Food and Beverage | $5,498.94 | 127 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $36,454.22 | 30 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $27,512.45 | 31 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $14,380.21 | 9 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $9,268.09 | 8 | 2025 |
Source payment records
|
|||||
| Descovy Normalized: descovy |
Drug | Gilead Sciences, Inc. | $7,913.12 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $294.27 | 6 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $150.30 | 13 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $124.84 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $115.32 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $89.61 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $71.57 | 3 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $53.43 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $39.28 | 2 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $31.49 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.78 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.77 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 86 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 71 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 140 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
86 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
140 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 22 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 382 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 296 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 227 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 40 |
| Gabapentin | Gabapentin | 148 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 145 | 42 |
| Losartan Potassium | Losartan Potassium | 142 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 140 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 136 | 41 |
| Metformin Hcl | Metformin Hcl | 132 | 37 |
| Potassium Chloride | Potassium Chloride | 115 | 35 |
| Furosemide | Furosemide | 105 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 103 | 32 |
| Jardiance | Empagliflozin | 99 | 27 |
| Lisinopril | Lisinopril | 92 | 23 |
| Tramadol Hcl | Tramadol Hcl | 89 | 18 |
| Pregabalin | Pregabalin | 88 | 26 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 86 | 12 |
| Ibuprofen | Ibuprofen | 84 | 42 |
| Omeprazole | Omeprazole | 83 | 26 |
| Trazodone Hcl | Trazodone Hcl | 83 | 23 |
| Nifedipine Er | Nifedipine | 82 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 25 |
| Eliquis | Apixaban | 81 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 17 |
| Dovato | Dolutegravir Sodium/Lamivudine | 71 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 27 |
| Linzess | Linaclotide | 66 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 43 |
| Alendronate Sodium | Alendronate Sodium | 54 | 18 |
| Azelastine Hcl | Azelastine Hcl | 51 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 15 |
| Carvedilol | Carvedilol | 50 | 16 |
| Prednisone | Prednisone | 49 | 33 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 47 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 12 |
| Ezetimibe | Ezetimibe | 44 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 31 |
| Promethazine Hcl | Promethazine Hcl | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Allopurinol | Allopurinol | 38 | 11 |
| Valsartan | Valsartan | 36 | 11 |
| Simvastatin | Simvastatin | 34 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Naproxen | Naproxen | 30 | 15 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 19 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 22 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 20 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 14 |
| Atenolol | Atenolol | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | 11 |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 12 |
| Fluconazole | Fluconazole | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $109,428.06 · 194 records | ViiV Healthcare Company | ABRYSVO, AIRSUPRA, APRETUDE, AREXVY, Biktarvy, CABENUVA, CAPVAXIVE, COMIRNATY, DOVATO, Descovy, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, Ohtuvayre, PIFELTRO, PREVNAR 20, REPATHA, RUKOBIA, TRELEGY ELLIPTA, UZEDY, Yeztugo, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error